Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 5/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.54 |
| ▸ | CHRNB2 | P17787 | 5/20 | 0.50 |
| ▸ | CHRNA4 | P43681 | 5/20 | 0.50 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.50 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.50 |
| ▸ | DPP4 | P27487 | 1/20 | 0.49 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.49 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.49 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31516268 | 0.92 | NOTUM (0.71) | NOTUMKDM4ECHRNB2CHRNA4CHRNB4 | |
| SCHEMBL4392645 | 0.86 | GPR119 (0.53) | NOTUMKDM4EGPR119CHRNB2CHRNA4 | |
| SCHEMBL30663949 | 0.86 | GPR119 (0.53) | NOTUMKDM4EGPR119CHRNB2CHRNA4 | |
| SCHEMBL15379126 | 0.84 | CHRNB2 (0.55) | NOTUMKDM4ECHRNB2CHRNA4CHRNB4 | |
| SCHEMBL26107713 | 0.84 | NOTUM (0.59) | NOTUMKDM4ECHRNB2CHRNA4CHRNB4 | |
| SCHEMBL31401347 | 0.82 | KDM4E (0.61) | KDM4EGPR119CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL30664035 | 0.82 | KDM4E (0.61) | KDM4EGPR119CHRNB2CHRNA4CHRNB4 | |
| SCHEMBL5585999 | 0.82 | CHRNB2 (0.54) | NOTUMKDM4EGPR119CHRNB2CHRNA4 | |
| SCHEMBL30098451 | 0.82 | CHRNB2 (0.54) | NOTUMKDM4EGPR119CHRNB2CHRNA4 | |
| SCHEMBL1222301 | 0.81 | NOTUM (0.79) | NOTUMKDM4ECYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117756779-A | Synthesis method of 1- (pyridine-3-yl) piperidine-4-carboxylic acid | 宁波职业技术学院 | 2024-03-26 | — | — | CN | claimed |
| CN-117756779-A | Synthesis method of 1- (pyridine-3-yl) piperidine-4-carboxylic acid | 宁波职业技术学院 | 2024-03-26 | — | — | CN | disclosed |
| CN-117756779-A | Synthesis method of 1- (pyridine-3-yl) piperidine-4-carboxylic acid | 宁波职业技术学院 | 2024-03-26 | — | — | CN | disclosed |
| CN-117756779-A | Synthesis method of 1- (pyridine-3-yl) piperidine-4-carboxylic acid | 宁波职业技术学院 | 2024-03-26 | — | — | CN | disclosed |
| CN-106061990-B | A kind of abiraterone derivative and preparation method thereof and medical usage | 四川海思科制药有限公司 | 2019-09-10 | — | — | CN | disclosed |
| CN-105646637-B | A kind of abiraterone derivative and preparation method thereof and medical usage | 四川海思科制药有限公司 | 2018-12-14 | — | — | CN | disclosed |
| CN-106061990-A | Abiraterone derivative, and preparation method therefor and medical applications thereof | 四川海思科制药有限公司 | 2016-10-26 | — | — | CN | disclosed |
| CN-105646637-A | Abiraterone derivative, preparation method and medical applications thereof | 四川海思科制药有限公司 | 2016-06-08 | — | — | CN | disclosed |
| WO-2016082792-A1 | ABIRATERONE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND MEDICAL APPLICATIONS THEREOF | 四川海思科制药有限公司 | 2016-06-02 | — | — | WO | disclosed |
| WO-2016082792-A1 | ABIRATERONE DERIVATIVE, AND PREPARATION METHOD THEREFOR AND MEDICAL APPLICATIONS THEREOF | 四川海思科制药有限公司 | 2016-06-02 | — | — | WO | disclosed |
| CN-102939283-B | Indazole compounds useful as ketohexokinase inhibitors | JANSSEN PHARMACEUTICA NV | 2015-06-03 | — | — | CN | disclosed |
| CN-102939283-A | Indazole compounds useful as ketohexokinase inhibitors | JANSSEN PHARMACEUTICA NV | 2013-02-20 | — | — | CN | disclosed |
| US-20060116368-A1 | 4-Piperidinecarboxamide modulators of vanilloid VR1 receptor | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-01 | — | — | US | disclosed |
| WO-2006058338-A2 | 4 - PIPERIDINECARBOXAMIDE DERIVATIVES AS MODULATORS OF VANILLOID VR1 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-01 | — | — | WO | disclosed |
| WO-2005019200-A2 | ARYL PIPERIDINE DERIVATIVES AS VLA-1 INTEGRIN ANTAGONISTS AND USES THEREOF | ICOS CORPORATION (US) | 2005-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060116368-A1 | 4-Piperidinecarboxamide modulators of vanilloid VR1 receptor | VDAC1, TRPV1, HVCN1 | NOTUM 3548/4885KDM4E 2664/4885CYP2C19 2800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.